News

Dishman Pharmaceuticals and Chemicals Ltd has informed  that Company's Wholly Owned Subsidiary company, namely Carbogen Amcis AG., Switzerland has acquired Creapharm Parenterals, a subsidiary of France based Greapharm Group.

Creapharm Parenterals is a contract development and manufacturing organization specializing in liquid, semi-solid and injectable aseptic dosage forms. As part of this acquisition, Creapharm Parenterals has changed its name to CARBOGEN AMCIS SAS.

The acquisition will extend CARBOGEN AMCIS' comprehensive range of development and manufacturing services by adding complementary formulation, lyophilization services and sterile GMP capabilities for the fast supply of drug products, including highly potents, for preclinical studies and clinical trials (Phase I, II & III).  

 Dishman Netherlands is pleased to announce that the Food & Drug Administration (FDA) successfully audited its facility in Veenendaal. The audit has been concluded without 483 Inspectional Observations.

The Audit was conducted over 4 days, from October 24 to 28, 2011 and covered two products; Cholesterol HP and Calcitriol.

“We are very proud of this significant achievement” states Henk Pluim, CEO of Dishman Netherlands. “It is allowing us to supply commercial APIs to the US market produced in our new HiPo facility. Our Quality Assurance Management is audited by customers and local authorities quite often, but a successful FDA inspection is the icing on the cake”.

Dishman Netherlands reaches agreement with Charles Bowman and Company to distribute all their Vitamin D3 products in North America; which will provide them with good growth opportunities for the animal feed market.

Veenendaal, the Netherlands, January 11, 2010        

Dishman Netherlands (Vitamins & Chemicals) announced recently their intentions to produce, market, and sell Vitamin D3 for the animal feed, pharmaceutical, and food markets during 2011, from their new facility in India which is currently being completed. All products from this facility will be GMP+ certified. Existing Vitamin D products from Dishman Netherlands include Cholecalciferol, Vitamin D3 resin, Dohyfral D3 2000AG (vitamin D3 in oil), and Ergocalciferol.

Charles Bowman and Company has been appointed the exclusive North American distributor for all Vitamin D products from Dishman Netherlands. The new products from Dishman Netherlands will include Dishman D3 500,000IU for use in the animal feed market worldwide, Dishman D3 100,000IU for the food market, and also other Vitamin D3 products in oil. The new Dishman D3-500 grade will provide a high quality D3-500 to meet the growing demand in the marketplace.

The history of Vitamin D production at Dishman Netherlands can be traced back to the 1920s and the invention of the process to produce vitamin D2 and thereafter in 1946 when the production of Vitamin D3 began.

This agreement strengthens Dishman Netherlands’ position as a leader in the manufacture and sale of Vitamin D3 in the North American market; particularly the animal feed market with Dishman D3-500. “Charles Bowman and Company was a natural choice for us as they have worked with Dishman Netherlands for many years with our Vitamin D products and Cholesterol,” stated Rodney Fox, International Sales and Marketing Director of Dishman Netherlands.  “They bring not only an understanding of our operations but also considerable experience in the areas of marketing and distribution of vitamins and nutrition ingredients to the feed, food, and pharmaceutical markets.”

Customers will benefit from cheaper, cleaner and greener processes

(AHMEDABAD, INDIA), February 17, 2010 – Today, the Dishman Group announced the formation of a strategic alliance with Codexis, Inc. a California based biotechnology company.  This strategic partnership covers the use of Codexis’ proprietary enzymatic biocatalysis technology for the manufacture of building blocks, intermediates and APIs for innovator pharmaceutical companies.  Dishman will be a preferred contract manufacturer for Codexis and will be able to offer the technology to its own customers.  In addition, the companies will work exclusively on certain select accounts. 

 

Codexis offers a wide selection of enzymes for the pharmaceutical synthesis of chiral compounds. With the majority of today’s drugs containing at least one chiral centre, this technology is directed at the very heart of pharmaceutical manufacture.  In comparison to traditional chemical synthesis, this technology offers a number of significant advantages: cost reduction compared with conventional complex transformations as a result of telescoped processes, increased specificity gives improved yields and often improved impurity profiles, significant reduction in environmental impact through reduce use of organic solvents and reduced energy processes.

 

This alliance will benefit Codexis and its customers by enabling Codexis to offer production of both intermediates and final APIs in Dishman’s world-class manufacturing asset base.  “We are delighted to be working with Codexis on this innovative technology.  It adds another dimension to the already extensive portfolio of services offered by the Dishman Group.  Our customers will benefit from cheaper, cleaner, greener processes manufactured in a low cost environment, a significant differentiator given today’s regulatory and market conditions ” said Nick Green, President Dishman CRAMS.

back   top   print